Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 May;126(5):458-463.
doi: 10.1111/bcpt.13365. Epub 2019 Dec 5.

Severe poisoning with naproxen causing coagulopathy

Bénédicte Lelièvre  1 , Isabelle Drouillard  2 , Chloé Thill  2 , Gaël Le Roux  3 , Chloé Bruneau  3 , Julien Mahé  4 , Marie Deguigne  3 , David Boels  3
Affiliations
Case Reports

Severe poisoning with naproxen causing coagulopathy

Bénédicte Lelièvre et al. Basic Clin Pharmacol Toxicol. 2020 May.

Abstract

Non-steroidal anti-inflammatory drugs (NSAIDs) are well known for their most frequent side effects (digestive, renal and metabolic disorders) but are lesser known for other effects, such as coagulation disturbances. In this issue, we report the case of a 58-year-old woman who ingested 26 g of naproxen in a suicidal attempt and developed cardiovascular shock, hypocoagulability and thrombopenia. Her outcome was positive (extubation 3 days after admission [D3], correction of haemostatic disruptions on D5 and of thrombopenia on D6). Naproxen plasma concentration was at a toxic concentration of 1320 mg/L at 6 hours after drug ingestion. Only few cases of hypocoagulopathy are reported with the NSAIDs, and this is the first case that can be attributed to naproxen. A possible explanation of this phenomenon following naproxen ingestion is an inhibition of thromboxane A2, usually attributed to NSAIDs, combined with an inhibition of activation of downstream the cascade.

Keywords: hypocoagulopathy; naproxen; thrombopenia; thromboxane A2.

PubMed Disclaimer

References

REFERENCES

    1. Bronstein AC, Spyker DA, Cantilena LR, et al. 2007 annual report of the American Association of Poison Control Centers' national Poisoning data system (NPDS):25th Annual report. Clin Tox. 2008;46:927-1057.
    1. Smolinske SC, Hall AH, Vandenberg SA, Spoerke DG, McBride PV. Toxic effects of nonsteroidal anti-inflammatory drugs in overdose. An overview of recent evidence on clinical effects and dose-response relationships. Drug Saf. 1990;5(4):252-274.
    1. Resume des caracteristiques du produit. Naproxene. Document consulted on the site http://www.agence-prd.ansm.sante.fr (2018, November the 11th).
    1. Turcant A, Prémel-Cabic A, Cailleux A, Allain P. Toxicological screening of drugs by microbore high-performance liquid chromatography with photodiode-array detection and ultraviolet spectral library searches. Clin Chem 1991;37(7):1210-1215.
    1. Mascolo A, Scavone C, Sessa M, et al. Can causality assessment fulfill the new European definition of adverse drug reaction? A review of methods used in spontaneous reporting. Pharmacol Res. 2017;123:122-129.

Publication types

Substances